Research Roundup

Debbie Rigby rounds up the latest in research news 

Intentional Weight Loss for Overweight and Obese Knee Osteoarthritis Patients: Is More Better?

In the Intensive diet and Exercise for Adults (IDEA) trial long0term weight loss of 20% bodyweight significantly improved health-related quality of life, and reduced pain and improved function, compared to 10% weight loss. Participants who lost 10% or more of their baseline body weight by the end of the study experienced a 50% reduction in pain and also reported significant improvements in mobility and daily function; whereas people who lost at least 20% of their baseline weight experienced a further 25% pain reduction and had better daily function than patients who lost no more than 10% of their weight.

Arthritis Care & Research 2018


Stakeholders’ views and experiences of pharmacist prescribing

This systematic review of 65 studies, mostly from the UK, Australia, Canada and USA, reports positive experiences and views for pharmacist prescribing, regardless of the stage of implementation. The main benefits described were: ease of patient access to healthcare services, improved patient outcomes, better use of pharmacists’ skills and knowledge, improved pharmacist job satisfaction, and reduced physician workload.

British Journal of Clinical Pharmacology, first published 5 June 2018.


Australian pharmacists’ knowledge of the efficacy and safety of complementary medicines

An online survey including views of 535 Australian pharmacists has confirmed basic knowledge of complementary medicines with a defined clinical effect. There were no statistically significantly different results from pharmacists with a nutritional qualification. The authors concluded specialised and targeted education focussing on relevant and efficacious complementary medicines with strong clinical evidence base is required.

Australian Journal of Primary Health, first published 8 May 2018.


Medicines associated with a risk of neuropsychiatric adverse events

In this Medicines Safety Update the TGA reminds health professionals of the importance of effectively communicating to patients and caregivers the potential risks and benefits of treatment with medicines associated with a risk of neuropsychiatric adverse events before prescribing. Medicines implicated include SSRIs, smoking cessation medicines, montelukast, and certain antiepileptics.

Medicines Safety Update 2018;9(2).


Previous First-ever agreement for AHPRA, police
Next Strong genetic link to hayfever confirmed

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply